• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Market-Moving News for June 28th

    6/28/24 8:37:11 AM ET
    $CARM
    $DJT
    $PTGX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Computer Software: Programming Data Processing
    Technology
    Get the next $CARM alert in real time by email

    PTGX: 11% | Protagonist Therapeutics To Join S&P SmallCap 600, Effective Prior To Opening Of Trading On July 3

    DJT: 16% | Trump Media & Technology Group shares are trading higher following Thursday's presidential debate.

    CARM: 95% | Carisma Therapeutics shares are trading higher after the company announced the nomination of the first in vivo CAR-M development candidate for hepatocellular carcinoma under collaboration with Moderna.

    Get the next $CARM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CARM
    $DJT
    $PTGX

    CompanyDatePrice TargetRatingAnalyst
    Protagonist Therapeutics Inc.
    $PTGX
    9/17/2025$72.00Overweight
    Barclays
    Protagonist Therapeutics Inc.
    $PTGX
    9/12/2025$73.00Outperform
    Leerink Partners
    Protagonist Therapeutics Inc.
    $PTGX
    6/17/2025$72.00Buy
    Citigroup
    Carisma Therapeutics Inc.
    $CARM
    12/12/2024$10.00 → $1.00Outperform → Neutral
    Robert W. Baird
    Carisma Therapeutics Inc.
    $CARM
    12/10/2024Buy → Neutral
    BTIG Research
    Protagonist Therapeutics Inc.
    $PTGX
    12/6/2024$47.00Neutral
    Goldman
    Protagonist Therapeutics Inc.
    $PTGX
    12/6/2024$62.00Outperform
    BMO Capital Markets
    Protagonist Therapeutics Inc.
    $PTGX
    11/5/2024$58.00Outperform
    Wedbush
    More analyst ratings

    $CARM
    $DJT
    $PTGX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Waddill William D. exercised 20,000 shares at a strike of $8.31 and sold $1,673,600 worth of shares (20,000 units at $83.68) (SEC Form 4)

    4 - Protagonist Therapeutics, Inc (0001377121) (Issuer)

    2/6/26 4:38:54 PM ET
    $PTGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Patel Dinesh V Ph D gifted 6,000 shares, exercised 48,273 shares at a strike of $10.79 and sold $4,063,743 worth of shares (48,273 units at $84.18), decreasing direct ownership by 1% to 574,505 units (SEC Form 4)

    4 - Protagonist Therapeutics, Inc (0001377121) (Issuer)

    1/27/26 9:21:26 PM ET
    $PTGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Ali Asif exercised 28,000 shares at a strike of $16.18 and sold $3,841,037 worth of shares (46,203 units at $83.13), decreasing direct ownership by 23% to 60,320 units (SEC Form 4)

    4 - Protagonist Therapeutics, Inc (0001377121) (Issuer)

    1/27/26 9:20:42 PM ET
    $PTGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CARM
    $DJT
    $PTGX
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Protagonist Therapeutics Inc.

    SCHEDULE 13G - Protagonist Therapeutics, Inc (0001377121) (Subject)

    2/10/26 11:19:49 AM ET
    $PTGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Protagonist Therapeutics Inc.

    SCHEDULE 13G/A - Protagonist Therapeutics, Inc (0001377121) (Subject)

    2/6/26 4:10:02 PM ET
    $PTGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Protagonist Therapeutics Inc.

    SCHEDULE 13G/A - Protagonist Therapeutics, Inc (0001377121) (Subject)

    1/30/26 2:43:24 PM ET
    $PTGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CARM
    $DJT
    $PTGX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    General Counsel and Secretary Glabe Scott bought $10,465 worth of shares (1,000 units at $10.46), increasing direct ownership by 0.31% to 326,236 units (SEC Form 4)

    4 - Trump Media & Technology Group Corp. (0001849635) (Issuer)

    11/19/25 8:48:25 PM ET
    $DJT
    Computer Software: Programming Data Processing
    Technology

    $CARM
    $DJT
    $PTGX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $CARM
    $DJT
    $PTGX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Barclays initiated coverage on Protagonist Therapeutics with a new price target

    Barclays initiated coverage of Protagonist Therapeutics with a rating of Overweight and set a new price target of $72.00

    9/17/25 8:03:08 AM ET
    $PTGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners initiated coverage on Protagonist Therapeutics with a new price target

    Leerink Partners initiated coverage of Protagonist Therapeutics with a rating of Outperform and set a new price target of $73.00

    9/12/25 7:52:34 AM ET
    $PTGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citigroup initiated coverage on Protagonist Therapeutics with a new price target

    Citigroup initiated coverage of Protagonist Therapeutics with a rating of Buy and set a new price target of $72.00

    6/17/25 7:50:36 AM ET
    $PTGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Institutional-Grade Token Architecture Positions Companies at the Center of Digital Finance

    Scalable, compliant infrastructure supports demand for regulated digital assets for growing number of industries  Market News Updates News Commentary NEW YORK, Feb. 4, 2026 /PRNewswire/ -- Digital finance is moving fast, and institutional-grade token architecture is becoming a core piece of the financial system. Large investors and institutions want digital assets that are secure, compliant, and easy to integrate with traditional finance. Tokenized infrastructure built for institutions helps make that possible by supporting regulated transactions, asset-backed tokens, and scalable platforms designed for real-world use, not just experimentation as Active Companies take notice that may include

    2/4/26 8:45:00 AM ET
    $COIN
    $DJT
    $GNLN
    Finance: Consumer Services
    Finance
    Computer Software: Programming Data Processing
    Technology

    Trump Media Reiterates Record Date for Digital Token Initiative

    SARASOTA, Fla., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Trump Media and Technology Group Corp. (Nasdaq, NYSE Texas: DJT) ("Trump Media" or the "Company"), operator of the social media platform Truth Social, the streaming platform Truth+, and the FinTech brand Truth.Fi, today confirmed the record date for its digital token initiative remains February 2, 2026. Ultimate beneficial owners of at least one whole share of DJT stock, including holders directly registered with the Company's transfer agent, Odyssey Transfer & Trust Company, will be eligible to receive tokens and associated incentives. As previously announced, Trump Media anticipates various rewards being made available to record-date sha

    2/2/26 8:30:00 AM ET
    $DJT
    Computer Software: Programming Data Processing
    Technology

    Yorkville America Equities and Truth Social ETFs Announce Proposed Acquisition of the God Bless America ETF (YALL)

    SARASOTA, Fla., Jan. 28, 2026 /PRNewswire/ -- Yorkville America Equities, LLC, sponsor and investment advisor for the Truth Social Funds, today announced that it has entered into an agreement to reorganize the God Bless America ETF (Ticker: YALL) into the Truth Social Funds. The respective Board of Trustees of the Truth Social Funds and the God Bless America ETF each also approved this transaction, which if approved by shareholders would be expected to close in the second quarter of 2026 (the "Transaction"). The Truth Social Funds and each of its existing ETF series are part of the Truth.Fi fintech brand from Trump Media & Technology Group Corp. (Nasdaq, NYSE Texas: DJT) ("Trump Media"), op

    1/28/26 9:32:00 AM ET
    $DJT
    Computer Software: Programming Data Processing
    Technology

    $CARM
    $DJT
    $PTGX
    Leadership Updates

    Live Leadership Updates

    View All

    Trump Media Announces Intention to Partner with Crypto.com to Launch ETFs

    America-First Investment Funds Slated to Launch in 2025 SARASOTA, Fla., March 24, 2025 (GLOBE NEWSWIRE) -- Trump Media and Technology Group Corp. (NASDAQ:DJT) ("TMTG" or the "Company"), operator of the social media platform Truth Social, the streaming platform Truth+, and the FinTech brand Truth.Fi, has signed a non-binding agreement to partner with Crypto.com, America's premier crypto trading platform, to launch a series of exchange-traded funds and exchange-traded products (collectively, "ETFs") through the Truth.Fi brand. The ETFs, made available through Crypto.com's broker dealer Foris Capital US LLC, are expected to comprise digital assets as well as securities with a Made in Americ

    3/24/25 5:00:00 PM ET
    $DJT
    Computer Software: Programming Data Processing
    Technology

    Truth Social Enhances Groups Feature

    New Update Overhauls Groups Layout, Improves Security SARASOTA, Fla., March 14, 2025 (GLOBE NEWSWIRE) -- Trump Media and Technology Group Corp. (NASDAQ:DJT) ("TMTG" or the "Company"), operator of the social media platform Truth Social, the streaming platform Truth+, and the FinTech brand Truth.Fi, released an update to the Truth Social app today to enhance the "Groups" feature. The layout for Groups—which allows users to join together and share content related to specific themes, hobbies, or interests—has been overhauled and improved, including with the addition of an explorer feed. The update makes it easier to discover new Groups and Groups content, and arranges for mor

    3/14/25 8:30:00 AM ET
    $DJT
    Computer Software: Programming Data Processing
    Technology

    Trump Media Joins Rumble Lawsuit to Stop Censorship

    SARASOTA, Fla., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Trump Media and Technology Group Corp. (NASDAQ:DJT) ("TMTG"), operator of the social media platform Truth Social, the streaming platform Truth+, and the FinTech brand Truth.Fi, joined Rumble today in filing a lawsuit to halt attempts by Brazilian Supreme Court Justice Alexandre de Moraes to force Rumble to censor accounts belonging to a U.S.-based Brazilian user. The lawsuit, filed in U.S. federal court in Tampa, Florida, aims to free Rumble from Moraes gag orders clearly intended to suppress the political opinions of a Rumble user. Such censorship would violate TMTG's and Rumble's commitment to free speech and—if enforced in the United St

    2/19/25 9:18:36 AM ET
    $DJT
    Computer Software: Programming Data Processing
    Technology

    $CARM
    $DJT
    $PTGX
    Financials

    Live finance-specific insights

    View All

    Institutional-Grade Token Architecture Positions Companies at the Center of Digital Finance

    Scalable, compliant infrastructure supports demand for regulated digital assets for growing number of industries  Market News Updates News Commentary NEW YORK, Feb. 4, 2026 /PRNewswire/ -- Digital finance is moving fast, and institutional-grade token architecture is becoming a core piece of the financial system. Large investors and institutions want digital assets that are secure, compliant, and easy to integrate with traditional finance. Tokenized infrastructure built for institutions helps make that possible by supporting regulated transactions, asset-backed tokens, and scalable platforms designed for real-world use, not just experimentation as Active Companies take notice that may include

    2/4/26 8:45:00 AM ET
    $COIN
    $DJT
    $GNLN
    Finance: Consumer Services
    Finance
    Computer Software: Programming Data Processing
    Technology

    Trump Media & Technology Group to Merge with TAE Technologies, a Premier Fusion Power Company, in All-Stock Transaction Valued at More Than $6 Billion

    Combined company expects to site and commence construction of the first utility-scale fusion power plant in 2026  Fusion power to blaze path toward America's A.I. dominance and energy security Conference call scheduled for 9 a.m. ET, December 18, 2025   SARASOTA, Fla. and FOOTHILL RANCH, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Trump Media & Technology Group Corp. (Nasdaq, NYSE Texas: DJT) ("TMTG") and TAE Technologies, Inc. ("TAE") today announced the signing of a definitive merger agreement to combine in an all-stock transaction valued at more than $6 billion. Upon closing, shareholders of each company will own approximately 50% of the combined company on a fully diluted equity basis

    12/18/25 6:30:00 AM ET
    $DJT
    Computer Software: Programming Data Processing
    Technology

    Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera

    Rusfertide plus current standard of care more than doubled clinical response rates across high- and low-risk PV groups, significantly reducing phlebotomy eligibility compared to placebo plus current standard of care, which was the primary endpoint All key secondary endpoints met with statistical significance, including a nearly three-fold reduction in the proportion of patients requiring phlebotomy and a four-fold improvement in hematocrit control in rusfertide arm compared to placebo arm, as well as improvements in patient-reported outcomes No serious adverse events considered related to rusfertide were reported Rusfertide has received Orphan Drug designation and Fast Track desig

    6/1/25 8:00:00 AM ET
    $PTGX
    $TAK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CARM
    $DJT
    $PTGX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Trump Media & Technology Group Corp.

    SC 13G/A - Trump Media & Technology Group Corp. (0001849635) (Subject)

    11/14/24 9:53:48 PM ET
    $DJT
    Computer Software: Programming Data Processing
    Technology

    Amendment: SEC Form SC 13G/A filed by Protagonist Therapeutics Inc.

    SC 13G/A - Protagonist Therapeutics, Inc (0001377121) (Subject)

    11/14/24 4:27:37 PM ET
    $PTGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Protagonist Therapeutics Inc.

    SC 13G/A - Protagonist Therapeutics, Inc (0001377121) (Subject)

    11/12/24 4:51:49 PM ET
    $PTGX
    Biotechnology: Pharmaceutical Preparations
    Health Care